Resistin, an adipocyte-derived signaling polypep-tide, was originally identified in 2001.5 Increased serum resistin levels are associated with metabolic syndrome and insulin resistance.6 In patients with NAFLD, serum resistin levels were higher than those in control lean and obese patients.7 This study was done to investigate serum resistin level and its receptor gene expression in liver biopsy as predictors for the severity in NAFLD. This evidence concerns the gene RETN and metabolic syndrome.